Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Severe hemophilia is characterized by frequent and lifelong bleeding, with more than 60% of
bleeds occurring into joints . Repeated joint bleeding leads to chronic synovitis, cartilage
damage and bony destruction. Currently available treatment of hemophilic arthropathy, such as
analgesics, NSAIDs, and hyaluronic acid (HA), are predominantly directed toward the
symptomatic relief of pain and inflammation, but they do little to reduce joint cartilage
degeneration.
Platelet-Rich Plasma (PRP) is a simple and minimally invasive method that provides a natural
concentrate of autologous growth factors from the blood. This method is now being
increasingly applied in clinical practice to treat musculoskeletal disorders, such as tendon
repairment and osteoarthritis. To the best of our knowledge, no study applies PRP for
arthropathy of knee joint in hemophilia patients. The aim of the study is to investigate the
efficacy, safety and duration of benefit of single PRP injection versus five weekly
intra-articular injections of HA in patients with hemophilic arthropathy of knee.